Day One Biopharmaceuticals Net Income
| DAWN Stock | USD 11.16 0.62 5.26% |
As of the 1st of February, Day One shows the Coefficient Of Variation of 830.99, downside deviation of 4.12, and Mean Deviation of 4.34. Day One Biopharmaceu technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Day One Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.2155 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -85.9 M | -90.2 M | |
| Net Loss | -85.9 M | -90.2 M | |
| Net Loss | -85.9 M | -90.2 M | |
| Net Loss | (1.17) | (1.23) | |
| Net Income Per E B T | 0.97 | 0.74 |
Day | Net Income | Build AI portfolio with Day Stock |
Evaluating Day One's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Day One Biopharmaceuticals's fundamental strength.
Latest Day One's Net Income Growth Pattern
Below is the plot of the Net Income of Day One Biopharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Day One Biopharmaceu financial statement analysis. It represents the amount of money remaining after all of Day One Biopharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Day One's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (95.5 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Day Net Income Regression Statistics
| Arithmetic Mean | (48,827,536) | |
| Coefficient Of Variation | (109.19) | |
| Mean Deviation | 43,559,518 | |
| Median | (12,634,000) | |
| Standard Deviation | 53,314,642 | |
| Sample Variance | 2842.5T | |
| Range | 176.3M | |
| R-Value | (0.75) | |
| Mean Square Error | 1337.8T | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | (7,892,131) | |
| Total Sum of Squares | 45479.2T |
Day Net Income History
Other Fundumenentals of Day One Biopharmaceu
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Day One Net Income component correlations
Day Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Day One is extremely important. It helps to project a fair market value of Day Stock properly, considering its historical fundamentals such as Net Income. Since Day One's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Day One's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Day One's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.
Day One 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Day One's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Day One.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Day One on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Day One Biopharmaceuticals or generate 0.0% return on investment in Day One over 90 days. Day One is related to or competes with Geron, Valneva SE, Arvinas, Replimune, Tyra Biosciences, Rezolute, and ArriVent BioPharma. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted thera... More
Day One Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Day One's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Day One Biopharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.12 | |||
| Information Ratio | 0.1137 | |||
| Maximum Drawdown | 39.62 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 13.81 |
Day One Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Day One's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Day One's standard deviation. In reality, there are many statistical measures that can use Day One historical prices to predict the future Day One's volatility.| Risk Adjusted Performance | 0.096 | |||
| Jensen Alpha | 0.7835 | |||
| Total Risk Alpha | 0.4753 | |||
| Sortino Ratio | 0.186 | |||
| Treynor Ratio | 1.61 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Day One's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Day One February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.096 | |||
| Market Risk Adjusted Performance | 1.62 | |||
| Mean Deviation | 4.34 | |||
| Semi Deviation | 3.66 | |||
| Downside Deviation | 4.12 | |||
| Coefficient Of Variation | 830.99 | |||
| Standard Deviation | 6.74 | |||
| Variance | 45.41 | |||
| Information Ratio | 0.1137 | |||
| Jensen Alpha | 0.7835 | |||
| Total Risk Alpha | 0.4753 | |||
| Sortino Ratio | 0.186 | |||
| Treynor Ratio | 1.61 | |||
| Maximum Drawdown | 39.62 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 13.81 | |||
| Downside Variance | 16.96 | |||
| Semi Variance | 13.4 | |||
| Expected Short fall | (6.28) | |||
| Skewness | 1.88 | |||
| Kurtosis | 5.41 |
Day One Biopharmaceu Backtested Returns
Day One appears to be slightly risky, given 3 months investment horizon. Day One Biopharmaceu secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. By reviewing Day One's technical indicators, you can evaluate if the expected return of 0.9% is justified by implied risk. Please utilize Day One's Coefficient Of Variation of 830.99, mean deviation of 4.34, and Downside Deviation of 4.12 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Day One holds a performance score of 10. The firm shows a Beta (market volatility) of 0.5, which means possible diversification benefits within a given portfolio. As returns on the market increase, Day One's returns are expected to increase less than the market. However, during the bear market, the loss of holding Day One is expected to be smaller as well. Please check Day One's downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Day One's price patterns will revert.
Auto-correlation | -0.3 |
Weak reverse predictability
Day One Biopharmaceuticals has weak reverse predictability. Overlapping area represents the amount of predictability between Day One time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Day One Biopharmaceu price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Day One price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 1.47 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Day Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Day One Biopharmaceuticals reported net income of (95.5 Million). This is 127.98% lower than that of the Biotechnology sector and 236.33% lower than that of the Health Care industry. The net income for all United States stocks is 116.72% higher than that of the company.
Day Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Day One's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Day One could also be used in its relative valuation, which is a method of valuing Day One by comparing valuation metrics of similar companies.Day One is currently under evaluation in net income category among its peers.
Day One Current Valuation Drivers
We derive many important indicators used in calculating different scores of Day One from analyzing Day One's financial statements. These drivers represent accounts that assess Day One's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Day One's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.0B | 1.4B | 1.2B | 1.2B | 1.4B | 1.4B | |
| Enterprise Value | 759.8M | 1.3B | 934.3M | 1.1B | 1.2B | 1.3B |
Day One ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Day One's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Day One's managers, analysts, and investors.Environmental | Governance | Social |
Day One Institutional Holders
Institutional Holdings refers to the ownership stake in Day One that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Day One's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Day One's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Goldman Sachs Group Inc | 2025-06-30 | 1.7 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.4 M | Hudson Bay Capital Management Lp | 2025-06-30 | 1.3 M | Millennium Management Llc | 2025-06-30 | 1.2 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 1.1 M | Renaissance Technologies Corp | 2025-06-30 | 1 M | Bank Of America Corp | 2025-06-30 | 965.4 K | Fmr Inc | 2025-06-30 | 11.3 M | Blackrock Inc | 2025-06-30 | 9.8 M |
Day Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 697.17 M | ||||
| Shares Outstanding | 102.68 M | ||||
| Shares Owned By Insiders | 16.93 % | ||||
| Shares Owned By Institutions | 85.98 % | ||||
| Number Of Shares Shorted | 11.38 M | ||||
| Price To Earning | 3.88 X | ||||
| Price To Book | 2.54 X | ||||
| Price To Sales | 8.57 X | ||||
| Revenue | 131.16 M | ||||
| Gross Profit | 119.56 M | ||||
| EBITDA | (86.32 M) | ||||
| Net Income | (95.5 M) | ||||
| Cash And Equivalents | 394.86 M | ||||
| Cash Per Share | 5.38 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 31.45 X | ||||
| Book Value Per Share | 4.39 X | ||||
| Cash Flow From Operations | (78.11 M) | ||||
| Short Ratio | 4.21 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Target Price | 22.44 | ||||
| Number Of Employees | 184 | ||||
| Beta | -1.27 | ||||
| Market Capitalization | 1.15 B | ||||
| Total Asset | 582.79 M | ||||
| Retained Earnings | (554.08 M) | ||||
| Working Capital | 488.88 M | ||||
| Net Asset | 582.79 M |
About Day One Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Day One Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Day One using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Day One Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Day One
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.Moving against Day Stock
| 0.81 | LYRA | Lyra Therapeutics | PairCorr |
| 0.72 | BCT | Briacell Therapeutics | PairCorr |
| 0.71 | IMNN | Imunon Inc | PairCorr |
| 0.67 | MBIO | Mustang Bio | PairCorr |
| 0.58 | SGMO | Sangamo Therapeutics | PairCorr |
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.